Neurotech International

Neurotech International ROE

The Return on Equity (ROE) of Neurotech International (NTI.AX) as of Oct 28, 2026 is -1,069.89 %. In the previous year, Return on Equity (ROE) was -358.73 % — a change of 198.24% (lower).

ROE

-1,069.89 %

YoY

198.24%

Last updated:

In 2026, Neurotech International's return on equity (ROE) was -1,069.89 %, a 198.24% increase from the -358.73 % ROE in the previous year.

The Neurotech International ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
-1,614.66 AUD
Jan 1, 2020
265.12 AUD
Jan 1, 2021
-192.43 AUD
Jan 1, 2022
-235.12 AUD
Jan 1, 2023
-196.67 AUD
Jan 1, 2024
-42.60 AUD
Jan 1, 2025
-358.73 AUD
Jan 1, 2026
-1,069.89 AUD
The Neurotech International ROE history
YEARROEYoY
-1,069.89 %+198.24%
-358.73 %+742.02%
-42.60 %-78.34%
-196.67 %-16.36%
-235.12 %+22.19%
-192.43 %-172.58%
265.12 %-116.42%
-1,614.66 %+1,612.09%
-94.31 %+0.47%
-93.87 %+224.26%
-28.95 %-55.35%
-64.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neurotech International Stock analysis

What does Neurotech International do? Neurotech International Ltd. generates revenue through the development and commercialization of medical devices and solutions, primarily targeting pediatric neurological disorders. The company's key product, Mente Autism, is a portable EEG headband that uses closed-loop neurofeedback to assist children with autism spectrum disorder (ASD) by improving relaxation and engagement. Clinical studies assess the neuro-protective and anti-inflammatory effects of its NTI/Dolce cannabis strains, which are part of its development program NTI164 that completed a Phase I/II trial for ASD treatment. The firm focuses on commercializing these neurological solutions for pediatric use in home therapy settings. The company's primary customers are families and healthcare providers managing children with autism spectrum disorder (ASD). Mente Autism is marketed as a home therapy device to increase engagement and reduce anxiety in autistic children with elevated delta-band brain activity. Neurotech International Ltd. leverages its clinical trial results to support the commercialization of Mente Autism and its NTI/Dolce cannabis strains, which are positioned as therapeutic solutions for neurological conditions. The firm's revenue streams are derived from the sale of Mente Autism devices and the potential future commercialization of its NTI/Dolce cannabis-based products. Neurotech International Ltd. operates within the medical device sector, emphasizing pediatric neurological solutions. Its products, including Mente Autism and the NTI/Dolce cannabis strains, are developed through clinical studies to address specific neurological disorders. The company's focus on home-based therapy for ASD patients differentiates its offerings in the market, targeting a niche segment of families seeking non-invasive, accessible treatments for children with autism. Neurotech International is one of the most popular companies on Eulerpool.

ROE Details

Decoding Neurotech International's Return on Equity (ROE)

Neurotech International's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Neurotech International's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Neurotech International's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Neurotech International’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Neurotech International stock

Return on Equity (ROE) of Neurotech International is -1,069.89 % in 2026.

Return on Equity (ROE) of Neurotech International changed from -358.73 % to -1,069.89 %, representing a 198.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Neurotech International since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Neurotech International with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Neurotech International

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Neurotech International